1966. Evaluating a Prototype Microbiome Health Index (MHI) as a Measure of Microbiome Restoration Using Data Derived From a Published Study of Fecal Microbiota Transplant (FMT) to Treat Recurrent Clostridium difficile Infections (rCDI)

摘要

BackgroundThere are efforts to develop FDA-approved microbiota-based drugs to restore the microbiome, notably for recurrent Clostridium difficile infections (rCDI). Given the lack of established biomarkers for microbiome restoration, we are evaluating unidimensional Microbiome Health Indices (MHI™). We previously presented a prototype MHI for clinical trials of RBX2660—a standardized microbiota restoration therapy in Phase 3 clinical development. Herein we assessed MHI for a published study of fecal microbiota transplant (FMT) for treating rCDI.